title: PROSPECTIVE EVALUATION OF A SUSTAINED-RELEASE DEXAMETHASONE INTRAVITREAL IMPLANT FOR CYSTOID MACULAR EDEMA IN QUIESCENT UVEITIS.
abstract: OBJECTIVE
  To investigate dexamethasone intravitreal implant (DEX implant; OZURDEX, Allergan, Inc) in the treatment of uveitic cystoid macular edema that had persisted in the absence of intraocular inflammation.
  
  
  METHODS
  In this prospective interventional case series, 10 patients with uveitic cystoid macular edema and quiescent uveitis were treated with dexamethasone intravitreal implant at baseline and evaluated monthly for one year. Patients were retreated whenever cystoid macular edema recurred. The primary outcome measure was best-corrected visual acuity (BCVA) at day 90.
  
  
  RESULTS
  At day 90, mean improvement from baseline BCVA was 14.4 letters (P = 0.0003), 70% of patients had a ≥10 letter BCVA improvement, 50% of patients had a ≥15 letter BCVA improvement, and the mean decrease from baseline central subfield retinal thickness was 140 μm (P = 0.008). Improvements were maintained through day 360 with retreatment as needed. At day 360, mean improvement in BCVA was 16.5 letters (P = 0.006) and the mean decrease in central subfield retinal thickness was 158 μm (P = 0.002). One patient experienced intraocular pressure >25 mmHg (managed with topical medication). Two phakic patients (2/8; 25%) had worsening of lens opacity requiring cataract extraction.
  
  
  CONCLUSIONS
  Dexamethasone intravitreal implant may be an effective treatment for patients with persistent cystoid macular edema in quiescent uveitis.
authors.affiliation: *Northern California Retina Vitreous Associates, Mountain View, California; †Department of Ophthalmology, University of California, San Francisco, San Francisco, California; and ‡Celgene Corporation, Berkeley Heights, New Jersey.
authors.forename: Rahul N
authors.initials: RN
authors.lastname: Khurana
authors.forename: Alok S
authors.initials: AS
authors.lastname: Bansal
authors.forename: Louis K
authors.initials: LK
authors.lastname: Chang
authors.forename: James D
authors.initials: JD
authors.lastname: Palmer
authors.forename: Chengqing
authors.initials: C
authors.lastname: Wu
authors.forename: Mark R
authors.initials: MR
authors.lastname: Wieland
mesh_terms: D000328:Adult; D003692:Delayed-Action Preparations; D003907:Dexamethasone / Q000008:administration & dosage*; D004343:Drug Implants; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D014605:Uveitis / Q000188:drug therapy*; D014792:Visual Acuity
chemical_list: D003692:Delayed-Action Preparations; D004343:Drug Implants; D005938:Glucocorticoids; D003907:Dexamethasone